Edgewise Therapeutics Appoints New CMO, Adds Directors
Ticker: EWTX · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $478,400, $520,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, appointment
TL;DR
Edgewise Therapeutics brings in new CMO Sarah Boyce and director David Epstein.
AI Summary
Edgewise Therapeutics, Inc. announced on January 8, 2025, the appointment of Dr. Sarah Boyce as Chief Medical Officer and the election of Dr. Boyce and Mr. David Epstein to its Board of Directors. The company also disclosed compensatory arrangements for these individuals.
Why It Matters
The appointment of a new Chief Medical Officer and board members can signal strategic shifts in the company's research and development direction and governance.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- Sarah Boyce (person) — Appointed Chief Medical Officer and elected to Board of Directors
- David Epstein (person) — Elected to Board of Directors
- January 8, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Sarah Boyce has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Dr. Sarah Boyce and Mr. David Epstein have been elected to the Board of Directors.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 8, 2025.
What is the principal executive office address for Edgewise Therapeutics, Inc.?
The principal executive office address is 1715 38th St., Boulder, CO 80301.
What is the telephone number for Edgewise Therapeutics, Inc.?
The telephone number is (720) 262-7002.
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-22 08:20:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share EWTX The Nasdaq
- $478,400 — s annual base salary was increased from $478,400 to $520,000, effective January 1, 2025.
- $520,000 — e salary was increased from $478,400 to $520,000, effective January 1, 2025. His annual
Filing Documents
- tm253635d1_8k.htm (8-K) — 27KB
- 0001104659-25-005075.txt ( ) — 195KB
- ewtx-20250108.xsd (EX-101.SCH) — 3KB
- ewtx-20250108_lab.xml (EX-101.LAB) — 33KB
- ewtx-20250108_pre.xml (EX-101.PRE) — 22KB
- tm253635d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Appointment of Chief Operating Officer On January 8, 2025, the Board of Directors (the " Board ") of Edgewise Therapeutics, Inc. (the " Company ") promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately. Dr. Derakhshan, age 45, previously served as our Chief Business Officer since September 2020. Prior to joining the Company, he was Chief Business Officer from July 2019 to September 2020 at VectivBio, a clinical-stage, rare disease focused biotechnology company. Prior to joining VectivBio, Dr. Derakhshan was Vice President, Head of Business Development from April 2017 to June 2019 at Therachon, a clinical stage biotechnology company acquired by Pfizer Inc. in 2019. Prior to Therachon, he was a director from January 2016 to April 2017 at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation after initially leading the New Products Global Commercial Insights and Analytics team from January 2015 to December 2015. Prior to joining Alexion, Dr. Derakhshan was a management consultant at Navigant Consulting, Inc. and Easton Associates, LLC, international management consulting firms. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in Biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK. He received a First-Class Honors BSc. with distinction in Biochemistry from the University of Surrey. In connection with the appointment of Dr. Derakhshan as the Company's Chief Operating Officer, his annual base salary was increased from $478,400 to $520,000, effective January 1, 2025. His annual target bonus was increased from 40% to 45% of his annual base salary starting in fiscal year 2025. There are no arrangements or under
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EDGEWISE THERAPEUTICS, INC. By: /s/ R. Michael Carruthers R. Michael Carruthers Chief Financial Officer Date: January 22, 2025